

Project title	BLUEPRINT: A BLUEPRINT of Haematopoietic Epigenomes
Project reference	282510
Funded under	European Union's Seventh Framework Programme for Research, Technological Development and Demonstration (FP7) / FP7-HEALTH
Duration of project	October 1, 2011 – September 30, 2016
Total budget	EUR 39 635 628.21
EU contribution	EUR 29 996 664.00
Coordinated by	Radboud University Nijmegen, The Netherlands
Topic(s)	HEALTH.2011.2.1.1-1 – High impact initiative on the human epigenome
Funding scheme	High impact, large-scale integrating project
Participants	<p>42 partner organisations (academia, research institutes and industrial partners)</p> <p>60 Principal Investigators</p> <p>12 countries</p>
Main research topics	<p>Generation of reference epigenomes of human primary blood cells of healthy donors and diseased counterparts from patients suffering from blood cancers or type 1 diabetes</p> <p>Advance the knowledge of underlying biological processes and mechanisms in health and disease</p> <p>Data quality assessment, data storage, data distribution and data analysis</p> <p>Epigenetic variation and use for improved diagnostics</p> <p>Development and validation of novel technologies for high-throughput epigenome mapping</p> <p>Identification and testing of new compounds interfering with regulators of epigenetic profiles for future personalized medicine</p>

Partnering organisations in BLUEPRINT at a glance

Participant	Principal Investigator	Organisation	Country
1	H.G. Stunnenberg / J. Martens	Radboud University Nijmegen	NL
2	S. Beck / T. Enver	University College London	UK
3	A. Ferguson-Smith / W. H. Ouwehand	University of Cambridge	UK
4	D. Schübeler	Friedrich Miescher Institute for Biomedical Research	CH
5	R. Siebert	Christian Albrechts University of Kiel	DE
6	A. Valencia	National Cancer Research Centre Spain	ES
7	P.G. Pelicci / S. Minucci	Institute of Molecular Oncology Foundation - European Institute of Oncology	IT
8	P. Flicek / E. Furlong / C. Merten	European Bioinformatics Institute European Molecular Biology Laboratory	UK DE
9	M. Stratton / D. Adams / N. Soranzo	Wellcome Trust Sanger Institute	UK
10	M. Esteller	Bellvitge Institute for Biomedical Research	ES
11	I. Gut	Centro Nacional de Analisis Genómico	ES
12	T. Lengauer H. Lehrach M. Vingron	Max Planck Institute for Bioinformatics Max Planck Institute for Molecular Genetics Max Planck Institute for Molecular Genetics	DE
13	J. Walter	University of Saarland	DE
14	L. Altucci	Second University of Naples	IT
15	R. Guigo / T. Graf / I. Gut / X. Estivill	Centre for Genomic Regulation	ES
16	D. Leslie / V. Rakan / J. Fitzgibbon	Queen Mary, University of London	UK
17	W. Reik	The Babraham Institute	UK
18	G. Drewes	Cellzome AG	DE
19	D. Allaer	Diagenode SA	BE
20	M. Seifert	Genomatix Software GmbH	DE

21	S. Spicuglia	Centre of Immunology of Marseille-Luminy	FR
22	E. Campo / I. Martin-Subero	Institut d'Investigacions Biomèdiques August Pi i Sunyer	ES
23	A. Tanay / I. Amit	Weizmann Institute of Science	IS
24	F. Grosveld	Erasmus University Medical Centre Rotterdam	NL
25	B. Böhm / R. Siebert	Universitätsklinikum Ulm	DE
26	A. Bird	University of Edinburgh	UK
27	A. Lemmark	Lund University	SE
28	K. Helin / B. Porse	University of Copenhagen	DK
29	A. Mai	Sapienza University of Rome	IT
30	M. Dermizakis / S. Antonarakis	University of Geneva	CH
31	E. Vellenga	University Medical Centre Groningen	NL
32	E. Macintyre	CNRS UMR-814 and Université Paris Descartes	FR
33	R. Küppers	Universitätsklinikum Essen	DE
34	M. Löffler	University of Leipzig	DE
35	D. Torrents	Barcelona Supercomputing Center	ES
36	C. Schacht	Eurice	DE
37	C. Bock	CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences	AU

Partners participating in BLUEPRINT at the start of the project, but no longer actively involved:

Participant	Organisation	Country
38	Halo genomics / Agilent Technologies	SE
39	Siena Biotech Spa	IT
40	Vivia Biotech S.L.	ES
41	Sigolis AB	SE
42	Oxford Nanopore Technologies	UK